(VTYX) Ventyx Biosciences - Overview
Stock: VTX958, Tamuzimod, VTX2735, VTX3242
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 116% |
| Relative Tail Risk | -29.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.13 |
| Alpha | 572.45 |
| Character TTM | |
|---|---|
| Beta | 1.478 |
| Beta Downside | 1.020 |
| Drawdowns 3y | |
|---|---|
| Max DD | 98.21% |
| CAGR/Max DD | -0.32 |
Description: VTYX Ventyx Biosciences January 17, 2026
Ventyx Biosciences (NASDAQ:VTYX) is a clinical-stage biotech focused on oral small-molecule therapies for autoimmune, inflammatory and neurodegenerative disorders. Its lead candidate, VTX958, is a selective allosteric TYK2 inhibitor being evaluated for Crohn’s disease, while its pipeline also includes Tamuzimod (S1P-receptor modulator for ulcerative colitis), VTX2735 (NLRP3 inflammasome inhibitor for cryopyrin-associated periodic syndrome), and VTX3232 (CNS-penetrant NLRP3 inhibitor in Phase 2a for early Parkinson’s disease and Phase 2 for obesity with cardiovascular risk).
Key operational metrics (as of the latest Q3 2024 filing) show a cash balance of roughly $45 million and a quarterly cash burn of $14–16 million, giving the company an estimated 2.5-year runway absent additional financing. The global market for Crohn’s disease therapies exceeds $10 billion and is projected to grow at a CAGR of ~5 % through 2030, providing a sizable addressable market for VTX958 if efficacy and safety data meet expectations.
Sector-wide, oral TYK2 inhibitors are gaining traction as a potentially safer alternative to biologics, and the NLRP3 inflammasome pathway is attracting significant R&D investment across pharma, indicating strong macro-level validation of Ventyx’s mechanistic focus.
Given the early-stage nature of the programs and the company’s reliance on successful Phase 2 read-outs, investors should closely monitor upcoming data releases and any partnership announcements that could de-risk the runway.
For a deeper dive into VTYX’s valuation dynamics and scenario analysis, you might find ValueRay’s research platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -106.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA 11.50 > 1.0 |
| NWC/Revenue: 13.1k% < 20% (prev 25.8k%; Δ -12.6k% < -1%) |
| CFO/TA -0.41 > 3% & CFO -87.8m > Net Income -106.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.3m) vs 12m ago 0.90% < -2% |
| Gross Margin: 53.11% > 18% (prev -0.33%; Δ 5344 % > 0.5%) |
| Asset Turnover: 0.57% > 50% (prev 0.36%; Δ 0.21% > 0%) |
| Interest Coverage Ratio: -14.21 > 6 (EBITDA TTM -113.6m / Interest Expense TTM -8.07m) |
Altman Z'' -15.00
| A: 0.90 (Total Current Assets 201.1m - Total Current Liabilities 11.3m) / Total Assets 211.5m |
| B: -2.99 (Retained Earnings -631.6m / Total Assets 211.5m) |
| C: -0.45 (EBIT TTM -114.7m / Avg Total Assets 256.3m) |
| D: -31.41 (Book Value of Equity -631.3m / Total Liabilities 20.1m) |
| Altman-Z'' Score: -39.83 = D |
Beneish M -2.74
| DSRI: 0.93 (Receivables 500.0k/400.0k, Revenue 1.45m/1.08m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.31 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.35 (Revenue 1.45m / 1.08m) |
| TATA: -0.09 (NI -106.6m - CFO -87.8m) / TA 211.5m) |
| Beneish M-Score: -2.74 (Cap -4..+1) = A |
What is the price of VTYX shares?
Over the past week, the price has changed by -0.29%, over one month by +78.39%, over three months by +69.50% and over the past year by +645.99%.
Is VTYX a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VTYX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.1 | 1.4% |
| Analysts Target Price | 14.1 | 1.4% |
| ValueRay Target Price | 15 | 7.7% |
VTYX Fundamental Data Overview February 04, 2026
Revenue TTM = 1.45m USD
EBIT TTM = -114.7m USD
EBITDA TTM = -113.6m USD
Long Term Debt = 10.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.18m USD (from shortTermDebt, last quarter)
Debt = 10.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -21.9m USD (from netDebt column, last quarter)
Enterprise Value = 819.0m USD (1.00b + Debt 10.0m - CCE 192.6m)
Interest Coverage Ratio = -14.21 (Ebit TTM -114.7m / Interest Expense TTM -8.07m)
EV/FCF = -9.32x (Enterprise Value 819.0m / FCF TTM -87.9m)
FCF Yield = -10.73% (FCF TTM -87.9m / Enterprise Value 819.0m)
FCF Margin = -6068 % (FCF TTM -87.9m / Revenue TTM 1.45m)
Net Margin = -7362 % (Net Income TTM -106.6m / Revenue TTM 1.45m)
Gross Margin = 53.11% ((Revenue TTM 1.45m - Cost of Revenue TTM 679.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.87 (Enterprise Value 819.0m / Total Assets 211.5m)
Interest Expense / Debt = 36.12% (Interest Expense 3.62m / Debt 10.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.6m (EBIT -114.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.86 (Total Current Assets 201.1m / Total Current Liabilities 11.3m)
Debt / Equity = 0.05 (Debt 10.0m / totalStockholderEquity, last quarter 191.4m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -21.9m / EBITDA -113.6m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -21.9m / FCF TTM -87.9m)
Total Stockholder Equity = 221.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.60% (Net Income -106.6m / Total Assets 211.5m)
RoE = -48.11% (Net Income TTM -106.6m / Total Stockholder Equity 221.6m)
RoCE = -49.51% (EBIT -114.7m / Capital Employed (Equity 221.6m + L.T.Debt 10.0m))
RoIC = -40.88% (negative operating profit) (NOPAT -90.6m / Invested Capital 221.6m)
WACC = 11.53% (E(1.00b)/V(1.01b) * Re(11.36%) + D(10.0m)/V(1.01b) * Rd(36.12%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.86%
Fair Price DCF = unknown (Cash Flow -87.9m)
EPS Correlation: 54.09 | EPS CAGR: 18.16% | SUE: 4.0 | # QB: 2
Revenue Correlation: 22.15 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.38 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.63 | Chg30d=-0.023 | Revisions Net=+0 | Growth EPS=-12.9% | Growth Revenue=+0.0%